Pearl Diagnostics is a Baltimore-based biotech spun out of Johns Hopkins University in 2014 that builds non-invasive urine-based diagnostic tests for lung infections. Its flagship MycoMEIA Aspergillus urine assay, which received FDA 510(k) clearance in August 2025 and CE approval for the EU, replaces invasive bronchoalveolar lavage procedures used to detect aspergillosis in transplant recipients, cancer patients, and immunocompromised individuals. The company is extending the same antigen-detection platform to other fungal and bacterial pathogens, including a Pseudomonas assay for cystic fibrosis patients.
1
Round
4
Tags
Apr 23, 2026
Latest raise
Funding activity · 1 round
Apr 23, 2026
$11.2M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
